Oruka Therapeutics (ORKA) SVP Arjun Agarwal Buys $150K of Stock

Arjun Agarwal, the Senior Vice President of Finance at Oruka Therapeutics, Inc. (ORKA), recently added to his holdings in the biotech company. On June 12, 2026, Agarwal purchased 9,459 shares at an average price of $15.88 each. The total value of the transaction came to $150,174.87, according to documents filed with the SEC.

This purchase was a direct acquisition and was not conducted under a pre-arranged Rule 10b5-1 trading plan. The timing of the buy is notable as it occurred shortly before several other executives sold shares in mid-June. Agarwal himself also engaged in a smaller, planned sale of 395 shares just three days later, on June 15, 2026, at a much higher price of $69.69.

Oruka Therapeutics Stock Activity

On Monday, shares of Oruka Therapeutics were priced at $69.89. The stock has been through a wide range lately, with a 52-week low of $14.89 and a 52-week high of $115.52. While the current price is about $26 below its 50-day moving average of $96.42, it remains above the 200-day moving average of $61.44. The company has a total market value of approximately $6.18 billion.

Recent Earnings Data

Oruka Therapeutics is a clinical-stage company and is not yet profitable, which means it does not have a traditional P/E ratio. For the most recent period, the company reported a loss of $2.04 per share. Its return on equity was negative 18.2%. Investors are looking toward November 11, 2026, when the company is expected to provide its next financial update. The company currently maintains a strong liquidity position with a current ratio of 38.51.

Insider Buying and Selling at Oruka Therapeutics, Inc.

There has been frequent activity among the company's leadership recently. On October 15, 2026, Chief Medical Officer Joana Goncalves sold 7,000 shares at $74.80 each, a trade valued at $523,647.60. Back in June 2026, CEO Lawrence Otto Klein sold 1,729 shares, and General Counsel Paul Quinlan sold 733 shares, both at a price of $69.69. Additionally, Chief Operating Officer Laura Lee Sandler sold 600 shares on June 15, 2026, at that same price point. Aside from Agarwal's purchase, these recent executive moves have mostly involved trimming positions.

Analysts Set New Price Targets

Wall Street remains very optimistic about the company's prospects. On September 24, 2026, Wedbush reiterated its Outperform rating with a $165.00 price target. That same day, HC Wainwright & Co. reaffirmed its Buy rating with a $120.00 target. Earlier in August, Guggenheim set a high price target of $200.00 while maintaining a Buy rating, and BTIG reiterated its Buy rating with a $151.00 target on August 11, 2026. Across 12 analyst opinions, the average price target sits at $155.00, suggesting significant potential upside from current levels.

Focus on Immunotherapy

Oruka Therapeutics is based in Menlo Park, California, and focuses on creating new antibody treatments for chronic skin diseases like psoriasis and other inflammatory conditions. Its lead projects are currently in phase 2 clinical trials, where researchers test if the drugs are safe and effective for patients. The company's work targets specific proteins in the immune system to help manage long-term inflammation.

What to Watch

Investors should keep an eye on the upcoming November earnings report for updates on the company's clinical trial progress. While Agarwal's purchase shows a commitment to the company, it is important to remember that insider trades and SEC filings are backward-looking and do not necessarily predict where the stock will go next. Future results will likely depend on whether the company's lead drug candidates can successfully move through the FDA approval process.